$FBIO
Fortress Biotech, Inc. Stock $fbio

$fbio Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-K Financial Statement

#000114420418015301 Filed on March 16, 2018

Income Statement

Concept	2017 Q4	2017 Q2	2017 Q1
Revenue	$7.543M	$4.404M	$2.778M
YoY Change	-47.64%	97.49%	320.91%
Cost Of Revenue	$1.810M	$878.0K	$469.0K
YoY Change	320.93%	170.99%
Gross Profit	-$126.8M	$3.526M	$2.309M
YoY Change	-1140.44%	84.99%
Gross Profit Margin	-1681.43%	80.06%	83.12%
Selling, General & Admin	$14.41M	$11.13M	$10.25M
YoY Change	67.75%	28.94%	29.28%
% of Gross Profit		315.77%	444.0%
Research & Development	$14.41M	$1.800M	$8.404M
YoY Change	36.2%	-12.62%	8.63%
% of Gross Profit		51.05%	363.97%
Depreciation & Amortization	-$1.200M	$180.0K	$682.0K
YoY Change	-244.58%	119.51%	16950.0%
% of Gross Profit		5.1%	29.54%
Operating Expenses	-$110.4M	$73.89M	$62.26M
YoY Change	-451.4%	325.49%	295.27%
Operating Profit	-$30.62M	-$25.50M	-$19.13M
YoY Change	-4.95%	49.6%	22.82%
Interest Expense	-$7.160M	$1.380M	$698.0K
YoY Change	258.0%	160.87%	12.58%
% of Operating Profit
Other Income/Expense, Net		$244.0K	$3.015M
YoY Change		-119.47%	-294.27%
Pretax Income	-$23.70M	-$22.95M	-$14.56M
YoY Change	11.27%	40.02%	-12.5%
Income Tax	$1.513M	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$10.41M	-$17.37M	-$11.98M
YoY Change	-40.26%	39.16%	-1.83%
Net Earnings / Revenue	-138.05%	-394.3%	-431.32%
Basic Earnings Per Share
Diluted Earnings Per Share	-$226.7K	-$428.4K	-$296.8K
COMMON SHARES
Basic Shares Outstanding	50.66M shares	50.33M shares	50.32M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q2	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$131.0M	$167.8M	$135.2M
YoY Change	44.43%	135.34%	66.09%
Cash & Equivalents	$94.95M	$161.2M	$150.9M
Short-Term Investments	$36.00M	$23.40M	$1.200M
Other Short-Term Assets	$43.60M	$12.90M	$9.500M
YoY Change	331.68%	706.25%	493.75%
Inventory	$171.0K	$299.0K	$204.0K
Prepaid Expenses
Receivables	$7.758M	$3.336M	$1.400M
Other Receivables	$600.0K	$5.900M	$5.400M
Total Short-Term Assets	$183.2M	$190.2M	$151.8M
YoY Change	67.08%	148.28%	80.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.116M	$7.329M	$7.400M
YoY Change	-3.52%	62.87%	184.62%
Goodwill	$18.65M	$18.65M	$18.65M
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments	$300.0K	$300.0K	$300.0K
YoY Change	0.0%	20.0%	20.0%
Other Assets	$258.0K	$16.30M	$16.30M
YoY Change	-34.52%	11.64%	8.67%
Total Long-Term Assets	$62.77M	$59.62M	$60.10M
YoY Change	2.74%	177.79%	191.75%
TOTAL ASSETS
Total Short-Term Assets	$183.2M	$190.2M	$151.8M
Total Long-Term Assets	$62.77M	$59.62M	$60.10M
Total Assets	$246.0M	$249.8M	$211.9M
YoY Change	44.06%	154.74%	102.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$27.60M	$25.00M	$24.90M
YoY Change	13.58%	390.2%	982.61%
Accrued Expenses	$17.63M	$12.37M	$11.12M
YoY Change	74.89%	45.56%	42.56%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$13.20M	$6.200M	$5.300M
YoY Change	560.0%
Total Short-Term Liabilities	$71.44M	$53.50M	$52.80M
YoY Change	26.29%	274.13%	388.89%
LONG-TERM LIABILITIES
Long-Term Debt	$49.30M	$40.70M	$27.80M
YoY Change	88.17%	86.7%	33.65%
Other Long-Term Liabilities	$4.739M	$5.026M	$5.000M
YoY Change	-5.48%	35.84%	108.33%
Total Long-Term Liabilities	$4.739M	$5.026M	$32.80M
YoY Change	-5.48%	-80.29%	41.38%
TOTAL LIABILITIES
Total Short-Term Liabilities	$71.44M	$53.50M	$52.80M
Total Long-Term Liabilities	$4.739M	$5.026M	$32.80M
Total Liabilities	$125.4M	$99.23M	$164.2M
YoY Change	42.94%	58.26%	172.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$312.1M	-$274.6M
YoY Change	27.27%
Common Stock	$51.00K	$800.0K
YoY Change	4.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$52.57M	$72.27M	$47.70M
YoY Change
Total Liabilities & Shareholders Equity	$246.0M	$249.8M	$211.9M
YoY Change	44.06%	154.69%	102.0%

Cashflow Statement

Concept	2017 Q4	2017 Q2	2017 Q1
OPERATING ACTIVITIES
Net Income	-$10.41M	-$17.37M	-$11.98M
YoY Change	-40.26%	39.16%	-1.83%
Depreciation, Depletion And Amortization	-$1.200M	$180.0K	$682.0K
YoY Change	-244.58%	119.51%	16950.0%
Cash From Operating Activities	-$20.87M	-$23.88M	-$11.48M
YoY Change	16.14%	223.58%	-1.42%
INVESTING ACTIVITIES
Capital Expenditures	-$3.010M	-$190.0K	$261.0K
YoY Change	393.44%	-91.2%	-88.62%
Acquisitions			$4.626M
YoY Change
Other Investing Activities	$8.790M	-$20.03M	-$680.0K
YoY Change	-1373.91%	872.33%	223.81%
Cash From Investing Activities	$5.780M	-$20.23M	-$942.0K
YoY Change	-544.62%	379.38%	-65.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$34.20M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	20.66M	54.42M	$58.16M
YoY Change	-20.42%	3480.26%	-2493.42%
NET CHANGE
Cash From Operating Activities	-20.87M	-23.88M	-$11.48M
Cash From Investing Activities	5.780M	-20.23M	-$942.0K
Cash From Financing Activities	20.66M	54.42M	$58.16M
Net Change In Cash	5.570M	10.31M	$45.74M
YoY Change	-16.74%	-202.28%	-372.77%
FREE CASH FLOW
Cash From Operating Activities	-$20.87M	-$23.88M	-$11.48M
Capital Expenditures	-$3.010M	-$190.0K	$261.0K
Free Cash Flow	-$17.86M	-$23.69M	-$11.74M
YoY Change	2.88%	353.83%	-15.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	315000	USD
CY2016Q4	us-gaap	Long Term Investments LongTermInvestments	1414000	USD
CY2017Q4	us-gaap	Long Term Investments LongTermInvestments	1390000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	15860000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	17387000	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	87000	USD
CY2016Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	481000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7758000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1830000	USD
CY2017Q4	us-gaap	Deposits With Clearing Organizations And Others Securities DepositsWithClearingOrganizationsAndOthersSecurities	1041000	USD
CY2016Q4	us-gaap	Deposits With Clearing Organizations And Others Securities DepositsWithClearingOrganizationsAndOthersSecurities	1030000	USD
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12680000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	183181000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9513000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	611000	USD
CY2017Q4	us-gaap	Assets Assets	245950000	USD
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017Q2	dei	Entity Public Float EntityPublicFloat	144508462	USD
CY2017	dei	Trading Symbol TradingSymbol	FBIO
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	51342513	shares
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	113915000	USD
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	38495000	USD
CY2016Q4	us-gaap	Minority Interest MinorityInterest	44473000	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	82968000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	245950000	USD
CY2016Q4	us-gaap	Assets Assets	170731000	USD
CY2017Q4	us-gaap	Deferred Revenue And Credits Current DeferredRevenueAndCreditsCurrent	786000	USD
CY2016Q4	us-gaap	Deferred Revenue And Credits Current DeferredRevenueAndCreditsCurrent	995000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	109634000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9061000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7376000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	394000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	170731000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	88294000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2080000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6370000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	283000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	17408000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	15223000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	52573000	USD
CY2017Q4	us-gaap	Minority Interest MinorityInterest	67929000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	120502000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	288792000	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	82190000	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	88000	USD
CY2017Q4	us-gaap	Receivables From Brokers Dealers And Clearing Organizations ReceivablesFromBrokersDealersAndClearingOrganizations	7395000	USD
CY2016Q4	us-gaap	Receivables From Brokers Dealers And Clearing Organizations ReceivablesFromBrokersDealersAndClearingOrganizations	3357000	USD
CY2017Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	1616000	USD
CY2016Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	1712000	USD
CY2017Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	1985000	USD
CY2016Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	2357000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	171000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	203000	USD
CY2017Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	618000	USD
CY2016Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	1790000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	18645000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	18645000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10065000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11940000	USD
CY2017Q4	us-gaap	Financial Instruments Sold Not Yet Purchased At Fair Value FinancialInstrumentsSoldNotYetPurchasedAtFairValue	151000	USD
CY2016Q4	us-gaap	Financial Instruments Sold Not Yet Purchased At Fair Value FinancialInstrumentsSoldNotYetPurchasedAtFairValue	298000	USD
CY2017Q4	fbio	Warrants Issuable Current WarrantsIssuableCurrent	5597000	USD
CY2016Q4	fbio	Warrants Issuable Current WarrantsIssuableCurrent	14359000	USD
CY2017Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	8528000	USD
CY2016Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	1000000	USD
CY2017Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	4700000	USD
CY2016Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1031000	USD
CY2017Q4	fbio	Contingently Issuable Liabilities Current ContingentlyIssuableLiabilitiesCurrent	0	USD
CY2016Q4	fbio	Contingently Issuable Liabilities Current ContingentlyIssuableLiabilitiesCurrent	1682000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	181000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	319000	USD
CY2017Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	10059000	USD
CY2016Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	3656000	USD
CY2017	us-gaap	Sales Revenue Net SalesRevenueNet	187584000	USD
CY2016	us-gaap	Sales Revenue Net SalesRevenueNet	16480000	USD
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	863000	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	51394000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-101208000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-65710000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-50531000	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	819000	USD
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	298000	USD
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	245000	USD
CY2017	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	226000	USD
CY2016	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	-1071000	USD
CY2015	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	-1675000	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2885000	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5580000	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3352000	USD
CY2017	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-32960000	USD
CY2016	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-16195000	USD
CY2015	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-5455000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-66876000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-55095000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-48428000	USD
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.61
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.38
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.24
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41658733	shares
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39962657	shares
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39146589	shares
CY2017	fbio	Interestexpenseandfinancefees Interestexpenseandfinancefees	5860000	USD
CY2016	fbio	Interestexpenseandfinancefees Interestexpenseandfinancefees	3690000	USD
CY2015	fbio	Interestexpenseandfinancefees Interestexpenseandfinancefees	1484000	USD
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-8391000	USD
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1039000	USD
CY2015	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	438000	USD
CY2017	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	-457000	USD
CY2016	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	-78000	USD
CY2015	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	0	USD
CY2017	us-gaap	Profit Loss ProfitLoss	-99836000	USD
CY2016	us-gaap	Profit Loss ProfitLoss	-71290000	USD
CY2015	us-gaap	Profit Loss ProfitLoss	-53883000	USD
CY2017	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2016	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2015	us-gaap	Other Noncash Expense OtherNoncashExpense	167000	USD
CY2017	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1314000	USD
CY2016	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1466000	USD
CY2015	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	314000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	14005000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	12128000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	14291000	USD
CY2017	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-284000	USD
CY2016	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	4346000	USD
CY2015	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	195000	USD
CY2017	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2016	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	350000	USD
CY2015	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1250000	USD
CY2017	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2016	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2015	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	79947000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	99949000	USD
CY2017	us-gaap	Proceeds From Mortgage Deposits ProceedsFromMortgageDeposits	42000	USD
CY2016	us-gaap	Proceeds From Mortgage Deposits ProceedsFromMortgageDeposits	0	USD
CY2015	us-gaap	Proceeds From Mortgage Deposits ProceedsFromMortgageDeposits	22000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-41629000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6060000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7885000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3481000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	204000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	739000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	9727000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5395000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5889000	USD
CY2017	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	176000	USD
CY2016	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	61000	USD
CY2015	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-1000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1165000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	944000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26000	USD
CY2017	us-gaap	Cost Of Goods Sold Amortization CostOfGoodsSoldAmortization	534000	USD
CY2016	us-gaap	Cost Of Goods Sold Amortization CostOfGoodsSoldAmortization	183000	USD
CY2015	us-gaap	Cost Of Goods Sold Amortization CostOfGoodsSoldAmortization	0	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5928000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1830000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-32000	USD
CY2015	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	158000	USD
CY2017	fbio	Amortization Of Forgivable Loans To Registered Representatives AmortizationOfForgivableLoansToRegisteredRepresentatives	693000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	203000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2017	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	-1172000	USD
CY2016	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	1634000	USD
CY2015	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	156000	USD
CY2017	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	0	USD
CY2016	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	175000	USD
CY2016	fbio	Amortization Of Forgivable Loans To Registered Representatives AmortizationOfForgivableLoansToRegisteredRepresentatives	176000	USD
CY2015	fbio	Amortization Of Forgivable Loans To Registered Representatives AmortizationOfForgivableLoansToRegisteredRepresentatives	0	USD
CY2017	fbio	Amortization Of Deferred Clearing Credit AmortizationOfDeferredClearingCredit	-209000	USD
CY2016	fbio	Amortization Of Deferred Clearing Credit AmortizationOfDeferredClearingCredit	-13000	USD
CY2015	fbio	Amortization Of Deferred Clearing Credit AmortizationOfDeferredClearingCredit	0	USD
CY2017	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	191000	USD
CY2016	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	47000	USD
CY2015	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	0	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-73000	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2017	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	-8391000	USD
CY2016	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	1039000	USD
CY2015	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	438000	USD
CY2017	us-gaap	Increase Decrease In Broker Dealer Related Receivables Payables Net IncreaseDecreaseInBrokerDealerRelatedReceivablesPayablesNet	4038000	USD
CY2016	us-gaap	Increase Decrease In Broker Dealer Related Receivables Payables Net IncreaseDecreaseInBrokerDealerRelatedReceivablesPayablesNet	4048000	USD
CY2015	us-gaap	Increase Decrease In Broker Dealer Related Receivables Payables Net IncreaseDecreaseInBrokerDealerRelatedReceivablesPayablesNet	0	USD
CY2017	us-gaap	Increase Decrease In Other Loans IncreaseDecreaseInOtherLoans	597000	USD
CY2016	us-gaap	Increase Decrease In Other Loans IncreaseDecreaseInOtherLoans	84000	USD
CY2015	us-gaap	Increase Decrease In Other Loans IncreaseDecreaseInOtherLoans	0	USD
CY2017	us-gaap	Increase Decrease In Marketable Securities Restricted IncreaseDecreaseInMarketableSecuritiesRestricted	-372000	USD
CY2016	us-gaap	Increase Decrease In Marketable Securities Restricted IncreaseDecreaseInMarketableSecuritiesRestricted	179000	USD
CY2015	us-gaap	Increase Decrease In Marketable Securities Restricted IncreaseDecreaseInMarketableSecuritiesRestricted	0	USD
CY2017	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2016	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	12000	USD
CY2015	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2017	us-gaap	Increase Decrease In Financial Instruments Sold Not Yet Purchased IncreaseDecreaseInFinancialInstrumentsSoldNotYetPurchased	-147000	USD
CY2016	us-gaap	Increase Decrease In Financial Instruments Sold Not Yet Purchased IncreaseDecreaseInFinancialInstrumentsSoldNotYetPurchased	298000	USD
CY2015	us-gaap	Increase Decrease In Financial Instruments Sold Not Yet Purchased IncreaseDecreaseInFinancialInstrumentsSoldNotYetPurchased	0	USD
CY2017	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	602000	USD
CY2016	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	66000	USD
CY2015	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	0	USD
CY2017	us-gaap	Payments For Mortgage Deposits PaymentsForMortgageDeposits	251000	USD
CY2016	us-gaap	Payments For Mortgage Deposits PaymentsForMortgageDeposits	6000	USD
CY2015	us-gaap	Payments For Mortgage Deposits PaymentsForMortgageDeposits	0	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	17400000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	15900000	USD
CY2017Q4	us-gaap	Pledged Assets Separately Reported Loans Pledged As Collateral At Fair Value PledgedAssetsSeparatelyReportedLoansPledgedAsCollateralAtFairValue	2500000	USD
CY2017	fbio	Percentage Of Tax Benefit Likely Of Being Realized PercentageOfTaxBenefitLikelyOfBeingRealized	0.5	pure
CY2017Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	27498000	USD
CY2017Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	4889000	USD
CY2017Q4	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash Deposites With Clearing Organizations BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashDepositesWithClearingOrganizations	1030000	USD
CY2017Q4	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Receivable From Brokers Dealers And Clearing Agencies BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivableFromBrokersDealersAndClearingAgencies	1607000	USD
CY2017Q4	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Securities Owned Fair Value BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSecuritiesOwnedFairValue	2178000	USD
CY2017Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	1985000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1030000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1148000	USD
CY2017Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	1132000	USD
CY2017Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther	353000	USD
CY2017Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	75817000	USD
CY2017Q4	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Compensation Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationPayable	14029000	USD
CY2017Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	6079000	USD
CY2017Q4	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Clearing And Marketing Credits BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredClearingAndMarketingCredits	1007000	USD
CY2017Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	707000	USD
CY2017Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	35228000	USD
CY2017Q4	us-gaap	Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue	17717000	USD
CY2017Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Less Noncontrolling Interest BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest	22872000	USD
CY2017	fbio	Cash And Cash Equivalents Acquired From Business Combination CashAndCashEquivalentsAcquiredFromBusinessCombination	27498000	USD
CY2017	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	22872000	USD
CY2017	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	4626000	USD
CY2017Q4	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Warrants Issuable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantsIssuable	13406000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15991000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	509000	USD
CY2017	us-gaap	Depreciation Depreciation	700000	USD
CY2016	us-gaap	Depreciation Depreciation	400000	USD
CY2015	us-gaap	Depreciation Depreciation	26000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2872000	USD
CY2017Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	475000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2397000	USD
CY2014Q1	us-gaap	Equity Method Investments EquityMethodInvestments	250000	USD
CY2014Q1	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.35	pure
CY2016Q4	us-gaap	Equity Method Investments EquityMethodInvestments	300000	USD
CY2017	us-gaap	Investments In And Advances To Affiliates At Fair Value Period Increase Decrease InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease	200000	USD
CY2015Q4	fbio	Warrants Issued WarrantsIssued	139592	shares
	fbio	Value Of Warrants Issued ValueOfWarrantsIssued	200000	USD
CY2015Q4	fbio	Value Of Warrants Issued ValueOfWarrantsIssued	600000	USD
CY2016Q4	fbio	Equity Securities Called By Warrant EquitySecuritiesCalledByWarrant	10000	USD
CY2017Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	1390000	USD
CY2017Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	1390000	USD
CY2015Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	2599000	USD
CY2016	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	19089000	USD
CY2016	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-1071000	USD
CY2016	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	78000	USD
CY2016	fbio	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Derivative Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisDerivativeLiabilityGainLossIncludedInEarnings	1039000	USD
CY2016	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	793000	USD
CY2017	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	4164000	USD
CY2015	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	11408000	USD
CY2017Q4	us-gaap	Long Term Debt LongTermDebt	67544000	USD
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	30224000	USD
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1035000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	2009000	USD
CY2017	fbio	Percentage Of Cash Flow Pursuant To Asc470 PercentageOfCashFlowPursuantToAsc470	0.1	pure
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	400000	USD
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5279000	USD
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2846000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1625000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1253000	USD
CY2017Q4	fbio	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	4046000	USD
CY2016Q4	fbio	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	394000	USD
CY2017Q4	fbio	Other Short Term Liabilities Related To Manufacturing Rights OtherShortTermLiabilitiesRelatedToManufacturingRights	0	USD
CY2016Q4	fbio	Other Short Term Liabilities Related To Manufacturing Rights OtherShortTermLiabilitiesRelatedToManufacturingRights	900000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17632000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10082000	USD
CY2017Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	0	USD
CY2017Q4	fbio	Lease Impairment Current LeaseImpairmentCurrent	0	USD
CY2016Q4	fbio	Lease Impairment Current LeaseImpairmentCurrent	128000	USD
CY2017Q4	fbio	Accrued Expenses Releted To Dr Falk Pharma Milestone AccruedExpensesReletedToDrFalkPharmaMilestone	3059000	USD
CY2016Q4	fbio	Accrued Expenses Releted To Dr Falk Pharma Milestone AccruedExpensesReletedToDrFalkPharmaMilestone	2634000	USD
CY2017Q4	fbio	Deferred Rent And Long Term Lease Abandonment Non Current DeferredRentAndLongTermLeaseAbandonmentNonCurrent	4739000	USD
CY2016Q4	fbio	Deferred Rent And Long Term Lease Abandonment Non Current DeferredRentAndLongTermLeaseAbandonmentNonCurrent	5014000	USD
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13701104	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13676979	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9889452	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	7700000	shares
CY2017	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	14005000	USD
CY2016	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	12128000	USD
CY2015	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	14291000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	11300000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	9900000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	6900000	USD
CY2017Q4	fbio	Employee Stock Purchase Plan Offering Fair Value Reckoning Percentage EmployeeStockPurchasePlanOfferingFairValueReckoningPercentage	0.85	pure
CY2017Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	22076	shares
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1.90
CY2017Q2	fbio	Employee Stock Purchase Plan Offering Fair Value Reckoning Percentage EmployeeStockPurchasePlanOfferingFairValueReckoningPercentage	0.85	pure
CY2017Q4	us-gaap	Share Price SharePrice	3.83
CY2017Q4	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	45657	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	3.26
CY2017Q4	fbio	Employee Stock Purchase Plan Offering Fair Value Reckoning Percentage EmployeeStockPurchasePlanOfferingFairValueReckoningPercentage	0.85	pure
CY2017Q2	us-gaap	Share Price SharePrice	2.24
CY2017	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	200000	USD
CY2016	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	0.1	USD
CY2015	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	45000	USD
CY2015Q4	us-gaap	Land Subject To Ground Leases LandSubjectToGroundLeases	6100	sqft
CY2015Q4	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2015Q4	fbio	Lease Expiration Period LeaseExpirationPeriod	P5Y
CY2014Q4	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2700000	USD
CY2012Q4	us-gaap	Land Subject To Ground Leases LandSubjectToGroundLeases	8700	sqft
CY2012	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1800000	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	400000	USD
CY2008Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04	pure
CY2016	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	USD
CY2015	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
CY2016	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	84000	USD
CY2015	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	24000	USD
CY2016Q4	fbio	Deferred Tax Assets Amortization Of Upfront Fees DeferredTaxAssetsAmortizationOfUpfrontFees	7277	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	10899	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	4025	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	6305	USD
CY2016Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	1095	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	106927	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	94687	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	12240	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	76486	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-32217000	USD
CY2016Q4	fbio	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	98	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	4450	USD
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.03	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.05	pure
CY2016Q4	us-gaap	Sales Revenue Net SalesRevenueNet	14405000	USD
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.02	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.01	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.33	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.44	pure
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.03	pure
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15571000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-17042000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-17180000	USD
CY2016Q4	fbio	Deferred Tax Assets Amortization Of In Process Research And Development DeferredTaxAssetsAmortizationOfInProcessResearchAndDevelopment	742	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Parents Basis In Discontinued Operation DeferredTaxLiabilitiesParentsBasisInDiscontinuedOperation	7790	USD
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	0.03	pure
CY2016	fbio	Effective Income Tax Rate Reconciliation Provision For Return EffectiveIncomeTaxRateReconciliationProvisionForReturn	0.02	pure
CY2015	fbio	Effective Income Tax Rate Reconciliation Provision For Return EffectiveIncomeTaxRateReconciliationProvisionForReturn	0	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.02	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.01	pure
CY2017	us-gaap	Revenues Revenues	187584000	USD
CY2017	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3658000	USD
CY2017	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10410000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52486000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	40487000	USD
CY2016	us-gaap	Revenues Revenues	16480000	USD
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	790000	USD
CY2016	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5774000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35134000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28229000	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	2230000	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	975000	USD
CY2016Q1	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	-1552000	USD
CY2016Q2	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	-1253000	USD
CY2016Q3	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	-710000	USD
CY2016Q4	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	-2065000	USD
CY2016Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	4438000	USD
CY2016Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	3911000	USD
CY2016Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	3975000	USD
CY2016Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	3871000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-12478000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-12981000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-17431000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	660000	USD
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	0	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14005000	USD
CY2016	fbio	Stock Issued During Period Value Cash Less Exercise Of Warrants StockIssuedDuringPeriodValueCashLessExerciseOfWarrants	0	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-12205000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	27000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	216000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12128000	USD
CY2015	fbio	Adjustments To Additional Paid In Capital Subsidiary Public Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering	51496000	USD
CY2016	fbio	Adjustments To Additional Paid In Capital Subsidiary Public Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering	36818000	USD
CY2015	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	59000	USD
CY2016	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	189000	USD
CY2015	fbio	Adjustments To Additional Paid In Capital Stock Issued For License Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForLicenseExpenses	958000	USD
CY2016	fbio	Adjustments To Additional Paid In Capital Stock Issued For License Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForLicenseExpenses	53000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14291000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	613000	USD
CY2016	fbio	Issuance Of Common Stock For At Market Offering IssuanceOfCommonStockForAtMarketOffering	434000	USD
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	191000	USD
CY2016	fbio	Adjustments To Additional Paid In Capital At Market Offering Costs AdjustmentsToAdditionalPaidInCapitalAtMarketOfferingCosts	-79000	USD
CY2016	fbio	Stock Cancelled During Period Value Restricted Stock Award StockCancelledDuringPeriodValueRestrictedStockAward	0	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	2006000	USD
CY2016	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	0	USD
CY2016	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	17643000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	793000	USD
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	36002000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	500000	USD
CY2016Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	0	USD
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	973000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	0	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50991285	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50991285	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48932023	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48932023	shares
CY2017Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	158015	shares
CY2016Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	0	shares
CY2017	fbio	Adjustments To Additional Paid In Capital Stock Issued For License Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForLicenseExpenses	1727000	USD
CY2017	fbio	Adjustments To Additional Paid In Capital Subsidiary Public Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering	95116000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	750000	USD
CY2017	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	0	USD
CY2017	fbio	Adjustments To Additional Paid In Capital Debt Discount Related To Opus Credit Facility AdjustmentsToAdditionalPaidInCapitalDebtDiscountRelatedToOpusCreditFacility	201000	USD
CY2017	us-gaap	Impairment Of Investments ImpairmentOfInvestments	250000	USD
CY2016	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2015	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2017	fbio	Change In Fairvalue Of Subsidiaries Assets And Liabilities ChangeInFairvalueOfSubsidiariesAssetsAndLiabilities	132000	USD
CY2016	fbio	Change In Fairvalue Of Subsidiaries Assets And Liabilities ChangeInFairvalueOfSubsidiariesAssetsAndLiabilities	1034000	USD
CY2015	fbio	Change In Fairvalue Of Subsidiaries Assets And Liabilities ChangeInFairvalueOfSubsidiariesAssetsAndLiabilities	0	USD
CY2015	fbio	Noncash Or Part Noncash Acquisition Restricted Cash NoncashOrPartNoncashAcquisitionRestrictedCash	0	USD
CY2017	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	0	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	6079000	USD
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> Use of Estimates</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company’s consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	0	USD
CY2015	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	0	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	27000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	216000	USD
CY2017	fbio	Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan	191000	USD
CY2016	fbio	Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan	189000	USD
CY2015	fbio	Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan	59000	USD
CY2017	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	95116000	USD
CY2017	fbio	Increase Decrease In Cash Deposits With Clearing Organisations IncreaseDecreaseInCashDepositsWithClearingOrganisations	-11000	USD
CY2016	fbio	Increase Decrease In Cash Deposits With Clearing Organisations IncreaseDecreaseInCashDepositsWithClearingOrganisations	0	USD
CY2015	fbio	Increase Decrease In Cash Deposits With Clearing Organisations IncreaseDecreaseInCashDepositsWithClearingOrganisations	0	USD
CY2017	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	0	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	1985000	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	0	USD
CY2017	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	1132000	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
CY2017	fbio	Noncash Or Part Noncash Acquisition Restricted Cash NoncashOrPartNoncashAcquisitionRestrictedCash	0	USD
CY2016	fbio	Noncash Or Part Noncash Acquisition Restricted Cash NoncashOrPartNoncashAcquisitionRestrictedCash	-353000	USD
CY2017	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	46000	USD
CY2016	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	39662000	USD
CY2015	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	57817000	USD
CY2017	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	0	USD
CY2016	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	2844000	USD
CY2015	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	6321000	USD
CY2017	fbio	Proceeds From Issuance Of At Market Offering ProceedsFromIssuanceOfAtMarketOffering	0	USD
CY2016	fbio	Proceeds From Issuance Of At Market Offering ProceedsFromIssuanceOfAtMarketOffering	434000	USD
CY2015	fbio	Proceeds From Issuance Of At Market Offering ProceedsFromIssuanceOfAtMarketOffering	0	USD
CY2015	fbio	Payment Of Cost Related To Atthemarket Offering PaymentOfCostRelatedToAtthemarketOffering	0	USD
CY2017	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	0	USD
CY2016	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	0	USD
CY2015	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	10000000	USD
CY2017	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2016	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2015	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	855000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	154207000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	42905000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	60916000	USD
CY2017	fbio	Noncash Or Part Noncash Acquisition Goodwill NoncashOrPartNoncashAcquisitionGoodwill	0	USD
CY2016	fbio	Noncash Or Part Noncash Acquisition Goodwill NoncashOrPartNoncashAcquisitionGoodwill	-18645000	USD
CY2015	fbio	Noncash Or Part Noncash Acquisition Goodwill NoncashOrPartNoncashAcquisitionGoodwill	0	USD
CY2017	us-gaap	Noncash Or Part Noncash Acquisition Accounts Receivable Acquired1 NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1	0	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Accounts Receivable Acquired1 NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1	4889000	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Accounts Receivable Acquired1 NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1	0	USD
CY2017	fbio	Noncash Or Part Noncash Acquisition Cash Deposits With Claening Organisations NoncashOrPartNoncashAcquisitionCashDepositsWithClaeningOrganisations	0	USD
CY2016	fbio	Noncash Or Part Noncash Acquisition Cash Deposits With Claening Organisations NoncashOrPartNoncashAcquisitionCashDepositsWithClaeningOrganisations	-1030000	USD
CY2015	fbio	Noncash Or Part Noncash Acquisition Cash Deposits With Claening Organisations NoncashOrPartNoncashAcquisitionCashDepositsWithClaeningOrganisations	0	USD
CY2017	fbio	Noncash Or Part Noncash Acquisition Receivables From Brokerdealers And Clearing Organizations NoncashOrPartNoncashAcquisitionReceivablesFromBrokerdealersAndClearingOrganizations	0	USD
CY2016	fbio	Noncash Or Part Noncash Acquisition Receivables From Brokerdealers And Clearing Organizations NoncashOrPartNoncashAcquisitionReceivablesFromBrokerdealersAndClearingOrganizations	-1607000	USD
CY2015	fbio	Noncash Or Part Noncash Acquisition Receivables From Brokerdealers And Clearing Organizations NoncashOrPartNoncashAcquisitionReceivablesFromBrokerdealersAndClearingOrganizations	0	USD
CY2017	us-gaap	Noncash Or Part Noncash Acquisition Investments Acquired1 NoncashOrPartNoncashAcquisitionInvestmentsAcquired1	0	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Investments Acquired1 NoncashOrPartNoncashAcquisitionInvestmentsAcquired1	2178000	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Investments Acquired1 NoncashOrPartNoncashAcquisitionInvestmentsAcquired1	0	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	0	USD
CY2017	us-gaap	Noncash Or Part Noncash Acquisition Employee Benefit Liabilities Assumed1 NoncashOrPartNoncashAcquisitionEmployeeBenefitLiabilitiesAssumed1	0	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Employee Benefit Liabilities Assumed1 NoncashOrPartNoncashAcquisitionEmployeeBenefitLiabilitiesAssumed1	14029000	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Employee Benefit Liabilities Assumed1 NoncashOrPartNoncashAcquisitionEmployeeBenefitLiabilitiesAssumed1	0	USD
CY2017	fbio	Noncash Or Part Noncash Acquisition Deferred Clearing And Marketing Credits Assumed NoncashOrPartNoncashAcquisitionDeferredClearingAndMarketingCreditsAssumed	0	USD
CY2016	fbio	Noncash Or Part Noncash Acquisition Deferred Clearing And Marketing Credits Assumed NoncashOrPartNoncashAcquisitionDeferredClearingAndMarketingCreditsAssumed	-1007000	USD
CY2015	fbio	Noncash Or Part Noncash Acquisition Deferred Clearing And Marketing Credits Assumed NoncashOrPartNoncashAcquisitionDeferredClearingAndMarketingCreditsAssumed	0	USD
CY2017	fbio	Non Cash Or Part Non Cash Acquisition Warrants Issuable NonCashOrPartNonCashAcquisitionWarrantsIssuable	0	USD
CY2016	fbio	Non Cash Or Part Non Cash Acquisition Warrants Issuable NonCashOrPartNonCashAcquisitionWarrantsIssuable	13406000	USD
CY2017	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	0	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	707000	USD
CY2017	fbio	Noncash Or Part Noncash Acquisition Noncontrolling Interests NoncashOrPartNoncashAcquisitionNoncontrollingInterests	0	USD
CY2016	fbio	Noncash Or Part Noncash Acquisition Noncontrolling Interests NoncashOrPartNoncashAcquisitionNoncontrollingInterests	17717000	USD
CY2015	fbio	Noncash Or Part Noncash Acquisition Noncontrolling Interests NoncashOrPartNoncashAcquisitionNoncontrollingInterests	0	USD
CY2017	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	4626000	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1300000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16500000	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1651000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	14340000	USD
CY2017	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	-234000	USD
CY2016	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	0	USD
CY2017	fbio	Reimbursement Of Cost Recognized As Revenue ReimbursementOfCostRecognizedAsRevenue	600000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1200000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1164000	USD
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	36000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	172000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	0	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	0	USD
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016	fbio	Reimbursement Of Cost Recognized As Revenue ReimbursementOfCostRecognizedAsRevenue	1000000	USD
CY2017Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	222000	USD
CY2017	fbio	Stock Issued During Period Value Preferred Stock StockIssuedDuringPeriodValuePreferredStock	22196000	USD
CY2017	fbio	Adjustments To Additional Paid In Capital Stock Issued For Settlement AdjustmentsToAdditionalPaidInCapitalStockIssuedForSettlement	2062000	USD
CY2017	fbio	Adjustments To Additional Paid In Capital Stock Issued For Research And Development Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses	200000	USD
CY2017	fbio	Adjustments To Additional Paid In Capital Stock Subsidiaries Stock Issued For Research And Development Expenses AdjustmentsToAdditionalPaidInCapitalStockSubsidiariesStockIssuedForResearchAndDevelopmentExpenses	50000	USD
CY2017	fbio	Common Shares Issuable Forinterest Payable CommonSharesIssuableForinterestPayable	500000	USD
CY2017	us-gaap	Dividends Preferred Stock DividendsPreferredStock	299000	USD
CY2017	fbio	Issuance Of Common Stock For Research And Development Expenses IssuanceOfCommonStockForResearchAndDevelopmentExpenses	200000	USD
CY2016	fbio	Issuance Of Common Stock For Research And Development Expenses IssuanceOfCommonStockForResearchAndDevelopmentExpenses	0	USD
CY2015	fbio	Issuance Of Common Stock For Research And Development Expenses IssuanceOfCommonStockForResearchAndDevelopmentExpenses	0	USD
CY2017	fbio	Issuance Of Subsidiaries Common Stock For Research And Development Expenses IssuanceOfSubsidiariesCommonStockForResearchAndDevelopmentExpenses	50000	USD
CY2016	fbio	Issuance Of Subsidiaries Common Stock For Research And Development Expenses IssuanceOfSubsidiariesCommonStockForResearchAndDevelopmentExpenses	0	USD
CY2015	fbio	Issuance Of Subsidiaries Common Stock For Research And Development Expenses IssuanceOfSubsidiariesCommonStockForResearchAndDevelopmentExpenses	0	USD
CY2017	us-gaap	Paid In Kind Interest PaidInKindInterest	541000	USD
CY2016	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2015	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	25000000	USD
CY2016	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2015	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2016Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	1414000	USD
CY2016Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	1414000	USD
CY2017	us-gaap	Proceeds From Subordinated Short Term Debt ProceedsFromSubordinatedShortTermDebt	28355000	USD
CY2016	us-gaap	Proceeds From Subordinated Short Term Debt ProceedsFromSubordinatedShortTermDebt	0	USD
CY2015	us-gaap	Proceeds From Subordinated Short Term Debt ProceedsFromSubordinatedShortTermDebt	0	USD
CY2016Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	5168000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	98182000	USD
CY2017Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	17387000	USD
CY2016Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	15860000	USD
CY2015Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	14586000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	131302000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104154000	USD
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	112768000	USD
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	20941000	USD
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	9914000	USD
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	226000	USD
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	1064000	USD
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	457000	USD
CY2017	fbio	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Derivative Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisDerivativeLiabilityGainLossIncludedInEarnings	-8391000	USD
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	21833000	USD
CY2017	fbio	Reimbursement Expenses reimbursementExpenses	9900000	USD
CY2017	us-gaap	Variable Interest Entity Activity Between Vie And Entity Expense VariableInterestEntityActivityBetweenVIEAndEntityExpense	16500000	USD
CY2016	us-gaap	Variable Interest Entity Activity Between Vie And Entity Expense VariableInterestEntityActivityBetweenVIEAndEntityExpense	17000000	USD
CY2017	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2016	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1682000	USD
CY2015	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2017Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	49749	shares
CY2017Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.02
CY2017	fbio	Payment Of Subordinated Short Term Debt Issuance Costs PaymentOfSubordinatedShortTermDebtIssuanceCosts	81000	USD
CY2016	fbio	Payment Of Subordinated Short Term Debt Issuance Costs PaymentOfSubordinatedShortTermDebtIssuanceCosts	0	USD
CY2015	fbio	Payment Of Subordinated Short Term Debt Issuance Costs PaymentOfSubordinatedShortTermDebtIssuanceCosts	0	USD
CY2017Q2	fbio	Exercise Price Of Warrant Discount Percentage ExercisePriceOfWarrantDiscountPercentage	0.33	pure
CY2016	us-gaap	Investments In And Advances To Affiliates At Fair Value Period Increase Decrease InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease	1100000	USD
CY2014Q1	fbio	Investment Write Down InvestmentWriteDown	300000	USD
CY2017	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	May - 2018
CY2017Q4	us-gaap	Equity Method Investments EquityMethodInvestments	300000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1779365	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	648864	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1130501	shares
CY2016	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	60668000	USD
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	20000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1110501	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1085501	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.73
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.75
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.51
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.37
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.78
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y3M25D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y11M5D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P3Y11M5D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P3Y11M12D
CY2015	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	32882000	USD
CY2015Q4	us-gaap	Minority Interest MinorityInterest	27427000	USD
CY2017Q4	fbio	Accrued Expenses Related Party AccruedExpensesRelatedParty	95000	USD
CY2016Q4	fbio	Accrued Expenses Related Party AccruedExpensesRelatedParty	0	USD
CY2016Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	53000	USD
CY2017	us-gaap	Interest Expense InterestExpense	5860000	USD
CY2016	us-gaap	Interest Expense InterestExpense	3690000	USD
CY2015	us-gaap	Interest Expense InterestExpense	1484000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.37
CY2017	fbio	Annual Management Services Agreement Fee Income Expense AnnualManagementServicesAgreementFeeIncomeExpense	0	USD
	fbio	Gross Proceeds From Fee Received GrossProceedsFromFeeReceived	15685000	USD
	fbio	Gross Proceeds From Fee Received GrossProceedsFromFeeReceived		USD
	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	14420000	USD
	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	1265000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	12506679	shares
CY2017Q4	fbio	Due To Related Parties Interest Expenses Current DueToRelatedPartiesInterestExpensesCurrent	669000	USD
CY2016Q4	fbio	Due To Related Parties Interest Expenses Current DueToRelatedPartiesInterestExpensesCurrent	77000	USD
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	62000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	2009000	USD
CY2016	fbio	Lease Sharing Agreements Contributions To Property Under Lease LeaseSharingAgreementsContributionsToPropertyUnderLease	4800000	USD
CY2017	fbio	Lease Sharing Agreements Contributions To Property Under Lease LeaseSharingAgreementsContributionsToPropertyUnderLease	163000	USD
CY2015	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	0	USD
CY2017	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2016	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2015	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2017	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> Reclassifications</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Certain prior period amounts may have been reclassified to conform to the current year presentation.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2804000	USD
CY2016	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2015	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.04	pure
CY2017	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	314000	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	5200000	USD
CY2016Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	5400000	USD
CY2017Q4	fbio	Related Party Other Investment Percentage In Entity By Familys Of Principal Stockholder Or Director RelatedPartyOtherInvestmentPercentageInEntityByFamilysOfPrincipalStockholderOrDirector	0	pure
CY2017	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	0	USD
	us-gaap	Payments For Fees PaymentsForFees	1265000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	666396000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	602451000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1351080000	USD
CY2017	fbio	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedIntrinsicValue	52400000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1351080000	USD
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2016Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2017Q4	fbio	Preferred Stock Shares Designated PreferredStockSharesDesignated	5000000	shares
CY2016Q4	fbio	Preferred Stock Shares Designated PreferredStockSharesDesignated	5000000	shares
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2017	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	56091000	USD
CY2016	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2015	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2017	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	20089000	USD
CY2016	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	0	USD
CY2015	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	0	USD
CY2017	us-gaap	Payments For Proceeds From Businesses And Interest In Affiliates PaymentsForProceedsFromBusinessesAndInterestInAffiliates	19000	USD
CY2016	us-gaap	Payments For Proceeds From Businesses And Interest In Affiliates PaymentsForProceedsFromBusinessesAndInterestInAffiliates	-4626000	USD
CY2015	us-gaap	Payments For Proceeds From Businesses And Interest In Affiliates PaymentsForProceedsFromBusinessesAndInterestInAffiliates	0	USD
CY2015	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	11406000	USD
CY2017	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	4164000	USD
CY2016	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	3838000	USD
CY2015	fbio	Non Cash Or Part Non Cash Acquisition Warrants Issuable NonCashOrPartNonCashAcquisitionWarrantsIssuable	0	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	0	USD
CY2016	fbio	Reimbursement Expenses reimbursementExpenses	11900000	USD
CY2016Q4	us-gaap	Pledged Assets Separately Reported Loans Pledged As Collateral At Fair Value PledgedAssetsSeparatelyReportedLoansPledgedAsCollateralAtFairValue	1000000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	44682000	USD
CY2017Q2	us-gaap	Sales Revenue Net SalesRevenueNet	50697000	USD
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	46886000	USD
CY2017Q4	us-gaap	Sales Revenue Net SalesRevenueNet	45319000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-62259000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-73890000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-79489000	USD
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-73154000	USD
CY2017Q1	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	3015000	USD
CY2017Q2	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	244000	USD
CY2017Q3	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	-3704000	USD
CY2017Q4	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	3330000	USD
CY2017Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	2580000	USD
CY2017Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	5584000	USD
CY2017Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	9191000	USD
CY2017Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	15605000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-11982000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-17365000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-27116000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-10413000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.67
CY2015	us-gaap	Revenues Revenues	863000	USD
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
CY2015	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2850000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29810000	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18734000	USD
CY2015Q4	us-gaap	Assets Assets	118610000	USD
CY2017Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	1600000	USD
CY2016Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	1700000	USD
CY2017	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	2761000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2976000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	3203000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	3084000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	3084000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	26600000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	41708000	USD
CY2017	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
CY2017	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.70	pure
CY2017Q4	us-gaap	Fair Value Assumptions Exercise Price FairValueAssumptionsExercisePrice	1.01
CY2017Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	55000	USD
CY2016Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	53000	USD
CY2016Q3	us-gaap	Land Subject To Ground Leases LandSubjectToGroundLeases	2295	acre
CY2016	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	5532000	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1200000	USD
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2500000	EUR
CY2016Q3	us-gaap	Legal Fees LegalFees	200000	USD
CY2017Q3	us-gaap	Legal Fees LegalFees	1500000	USD
CY2017Q4	us-gaap	Payments For Fees PaymentsForFees	2700000	USD
CY2017Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.28	pure
CY2015Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	10000	shares
CY2015Q3	fbio	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	2500	shares
CY2015Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.00
CY2015Q3	fbio	Stock Issued During Period Value Of Warrants Excercised StockIssuedDuringPeriodValueOfWarrantsExcercised	50000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	53000000	USD
CY2016Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	10000	shares
CY2017	fbio	Net Proceeds From Issuance Of Warrants NetProceedsFromIssuanceOfWarrants	51500000	USD
CY2017	fbio	Stock Issued For Exercise Of Warrants StockIssuedForExerciseOfWarrants	10000	shares
CY2017	fbio	Warrant Purchase Price Per Unit WarrantPurchasePricePerUnit	50000	USD
CY2017Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	7.00	shares
CY2017Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2500
CY2015Q3	fbio	Percentage Of Placement Of Agent Fee PercentageOfPlacementOfAgentFee	0.10	pure
CY2017	fbio	Percentage Of Placement Of Agent Fee PercentageOfPlacementOfAgentFee	0.1	pure
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-85430000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45812000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20378000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-98323000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-71290000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-53883000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1513000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017	fbio	Adjustments To Additional Paid In Capital Acquisition Of Business AdjustmentsToAdditionalPaidInCapitalAcquisitionOfBusiness	-211000	USD
CY2017	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	9914000	USD
CY2016	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4609000	USD
CY2015	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2017	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	104000	USD
CY2016	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	594000	USD
CY2015	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	27148000	USD
CY2016	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8967000	USD
CY2015	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	48423000	USD
CY2017	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2016	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	920000	USD
CY2015	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2017	us-gaap	Proceeds From Unsecured Lines Of Credit ProceedsFromUnsecuredLinesOfCredit	2500000	USD
CY2016	us-gaap	Proceeds From Unsecured Lines Of Credit ProceedsFromUnsecuredLinesOfCredit	7000000	USD
CY2015	us-gaap	Proceeds From Unsecured Lines Of Credit ProceedsFromUnsecuredLinesOfCredit	0	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1513000	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1074000	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	439000	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	71616	USD
CY2017Q4	fbio	Deferred Tax Assets Amortization Of In Process Research And Development DeferredTaxAssetsAmortizationOfInProcessResearchAndDevelopment	557	USD
CY2017Q4	fbio	Deferred Tax Assets Amortization Of Upfront Fees DeferredTaxAssetsAmortizationOfUpfrontFees	13648	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	10682	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5166	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	7376	USD
CY2017Q4	fbio	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	75	USD
CY2017Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	109120	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	101645	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	7475	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	3321	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Parents Basis In Discontinued Operation DeferredTaxLiabilitiesParentsBasisInDiscontinuedOperation	3469	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.08	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.01	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.02	pure
CY2017	fbio	Effective Income Tax Rate Reconciliation Provision For Return EffectiveIncomeTaxRateReconciliationProvisionForReturn	0.01	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.01	pure
CY2016	fbio	Effective Income Tax Rate Reconciliation Change In Federal Rate Percent EffectiveIncomeTaxRateReconciliationChangeInFederalRatePercent	0	pure
CY2015	fbio	Effective Income Tax Rate Reconciliation Change In Federal Rate Percent EffectiveIncomeTaxRateReconciliationChangeInFederalRatePercent	0	pure
CY2017	fbio	Effective Income Tax Rate Reconciliation Change In State Rate Percent EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent	0.02	pure
CY2016	fbio	Effective Income Tax Rate Reconciliation Change In State Rate Percent EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent	0	pure
CY2015	fbio	Effective Income Tax Rate Reconciliation Change In State Rate Percent EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent	0	pure
CY2017	fbio	Effective Income Tax Rate Reconciliation Intercompany Elimination Adjustments Percent EffectiveIncomeTaxRateReconciliationIntercompanyEliminationAdjustmentsPercent	-0.03	pure
CY2016	fbio	Effective Income Tax Rate Reconciliation Intercompany Elimination Adjustments Percent EffectiveIncomeTaxRateReconciliationIntercompanyEliminationAdjustmentsPercent	0	pure
CY2015	fbio	Effective Income Tax Rate Reconciliation Intercompany Elimination Adjustments Percent EffectiveIncomeTaxRateReconciliationIntercompanyEliminationAdjustmentsPercent	0	pure
CY2017	fbio	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantsPercent	0.03	pure
CY2016	fbio	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantsPercent	0	pure
CY2015	fbio	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantsPercent	0	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.07	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	0.04	pure
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.02	pure
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	36127000	USD
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	24295000	USD
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01	pure
CY2017Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	14846000	USD
CY2017	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	7500000	USD
CY2017	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	100889000	USD
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	USD
CY2017Q4	fbio	Employee Service Share Based Compensation Vested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationVestedAwardsTotalCompensationCostNotYetRecognized	0	USD
CY2017Q4	us-gaap	Prepaid Rent PrepaidRent	1000000	USD
CY2015Q4	us-gaap	Prepaid Rent PrepaidRent	200000	USD
CY2017Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	34200000	USD
CY2017Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	125000	shares
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	800000	USD
CY2017	fbio	Common Shares Issued For Pik Interest Expense CommonSharesIssuedForPikInterestExpense	541000	USD
CY2017	fbio	Issuance Of Common Stock For Pik Interest Expense IssuanceOfCommonStockForPikInterestExpense	500000	USD
CY2016	fbio	Issuance Of Common Stock For Pik Interest Expense IssuanceOfCommonStockForPikInterestExpense	0	USD
CY2015	fbio	Issuance Of Common Stock For Pik Interest Expense IssuanceOfCommonStockForPikInterestExpense	0	USD
CY2016	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	0	USD
CY2017	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	299000	USD
CY2017	us-gaap	Revenue Recognition Sales Returns Reserve For Sales Returns RevenueRecognitionSalesReturnsReserveForSalesReturns	1200000	USD
CY2016	us-gaap	Revenue Recognition Sales Returns Reserve For Sales Returns RevenueRecognitionSalesReturnsReserveForSalesReturns	100000	USD
CY2017Q4	fbio	Expected Cost Of Construction ExpectedCostOfConstruction	3500000	USD
CY2017Q4	fbio	Expected Cost Of Equipment ExpectedCostOfEquipment	2500000	USD
CY2017Q4	us-gaap	Payments For Fees PaymentsForFees	100000	USD
CY2016Q4	fbio	Accrued Coupon Expense Current AccruedCouponExpenseCurrent	463000	USD
CY2017Q4	fbio	Accrued Coupon Expense Current AccruedCouponExpenseCurrent	1087000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	70523000	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	84273000	USD
CY2017	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	3365000	USD
CY2016	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	3785000	USD
CY2015	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	10448000	USD
CY2017	fbio	Payment Of Unsecured Notes Payable PaymentOfUnsecuredNotesPayable	3608000	USD
CY2016	fbio	Payment Of Unsecured Notes Payable PaymentOfUnsecuredNotesPayable	6392000	USD
CY2015	fbio	Payment Of Unsecured Notes Payable PaymentOfUnsecuredNotesPayable	0	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	685	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	0	USD
CY2017	fbio	Effective Income Tax Rate Reconciliation Change In Federal Rate Percent EffectiveIncomeTaxRateReconciliationChangeInFederalRatePercent	-0.43	pure
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2017Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	43292	shares
CY2017Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	101600000	USD
CY2017Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	0	USD
CY2016Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	0	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2550000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2550000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2551000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2550000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2550000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1589000	USD
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1411000	USD
CY2016Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	263000	USD
CY2017Q4	us-gaap	Notes Payable NotesPayable	66509000	USD
CY2016Q4	us-gaap	Notes Payable NotesPayable	28215000	USD

Files In Submission

Name	View Source	Status
0001144204-18-015301-index-headers.html	Edgar Link	pending
0001144204-18-015301-index.html	Edgar Link	pending
0001144204-18-015301.txt	Edgar Link	pending
0001144204-18-015301-xbrl.zip	Edgar Link	pending
fbio-20171231.xml	Edgar Link	completed
fbio-20171231.xsd	Edgar Link	pending
fbio-20171231_cal.xml	Edgar Link	unprocessable
fbio-20171231_def.xml	Edgar Link	unprocessable
fbio-20171231_lab.xml	Edgar Link	unprocessable
fbio-20171231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv487010_10k.htm	Edgar Link	pending
tv487010_ex10-39.htm	Edgar Link	pending
tv487010_ex21-1.htm	Edgar Link	pending
tv487010_ex23-1.htm	Edgar Link	pending
tv487010_ex23-2.htm	Edgar Link	pending
tv487010_ex31-1.htm	Edgar Link	pending
tv487010_ex31-2.htm	Edgar Link	pending
tv487010_ex32-1.htm	Edgar Link	pending
tv487010_ex32-2.htm	Edgar Link	pending
tv487010_img1.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FBIO
Fortress Biotech, Inc. Stock $fbio

2017 Q4 Form 10-K Financial Statement

#000114420418015301 Filed on March 16, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO Fortress Biotech, Inc. Stock $fbio

2017 Q4 Form 10-K Financial Statement

#000114420418015301 Filed on March 16, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO
Fortress Biotech, Inc. Stock $fbio